Big Cypress Acquisition registered additional units and now plans to offer 10 million units at $10 each to raise $100 million in an IPO. That represents a 33 percent increase from the initial filing in December to offer 75 million units.
The new SPAC plans to target a business in the life sciences industry.
Big Cypress is led by CEO Samuel J. Reich, who co-founded Biscayne Neurotherapeutics in 2011 and served as its executive chairman until the company was sold Supernus Pharmaceuticals in 2018.
The SPAC intends to list on the Nasdaq under BCYPU. Read more.